US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on Wednesday that the US Food and Drug Administration (FDA) has approved the Nuvaxovid 2025-2026 Formula for the prevention of COVID-19.
The formula was approved for adults aged 65 years and older, or individuals from 12 years with at least one underlying condition that puts them at high risk of severe outcomes from COVID-19.
Clinical and preclinical data have previously shown that Nuvaxovid is safe and effective for the prevention of COVID-19, and induces immunity across currently circulating JN.1 lineage strains, including NB.1.8.1, LP.8.1, XFG, XFC, LF.7 and XEC.
According to Novavax, Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the United States for the 2025-2026 vaccination season.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses